Imsidolimab

艾米司利单抗

Report date: 2026/04/23 20:00:25

Base Information

Drug NameImsidolimab
Drug Alias NameANB019ANB 019ANB-019
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionInterleukin-36 receptor inhibitors
TargetsInterleukin-36 receptor
Therapy Area/IndicationsPalmoplantar pustulosisGeneralised pustular psoriasisAcne Vulgaris +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[19] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaIND
Originator CompaniesAnaptysbio Inc
China Registration ClassN/A

Develop Information

Active CompaniesVanda Pharmaceuticals IncAnaptysbio IncShanghai PPC Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsGeneralised pustular psoriasisAcne VulgarisHidradenitis Suppurativa
Inactive IndicationsPalmoplantar pustulosisAcneiform EruptionsIchthyosis

Other Information

ATC CodeN/A
Related LinksN/A